Introduction:

To evaluate the effectiveness and safety of evolocumab in the reduction of analytical data related to cholesterol.

Material and methods:

Observational, descriptive and retrospective study of patients treated with evolocumab for 12 or more weeks (May 2017-May 2019). Variables collected: demographic, related to treatment and appearance of cardiovascular events. Effectiveness: analytical data, mainly low density lipoprotein cholesterol (LDL-c) basal and at week 12, 24 and 48. Safety: adverse events.

Results:

79 patients were identified, mostly males (54%), mean age 62 years. A 23% of patients had heterozygous familial hypercholesterolemia and 1% homozygous. A 58% of patients had cardiovascular disease and a 96% had been treated with statins. A 63% os patients were treated with evolocumab in combination. Effectiveness: mean level of LDL-c basal, at week 12, 24 and 48, were 151 mg/dL, 71 mg/dL, 74 mg/dL and 72 mg/dL, respectively. At week 12, LDL-c had been reduced by 53%, data kept constant. Safety: 59% of patients presented adverse events, 1% had to reduce the posology and 4% had to stop treatment. At the end of the study, 92% of patients continued treatment after a median of 49 weeks. During the treatment, 3% of patients suffered a cardiovascular event.

Conclusions:

Evolocumab reduces LDL-c levels by approximately half in week 12, data maintained over time and similar to those published. In safety, the results obtained are similar to those previously found and in summary of product characteristics. Therefore, evolocumab is a therapeutic alternative for the treatment of hypercholesterolemia.

        · resumen en Español     · texto en Español     · Español ( pdf )